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AbstrACt
Introduction The majority of older patients with a 
transtibial amputation are prescribed a standard (more 
rigid, not self-aligning) prosthesis. These are mostly 
suitable for level walking, and cannot adjust to different 
sloped surfaces. This makes walking more difficult and 
less energy efficient, possibly leading to longer term 
disuse. A Cochrane Review concluded that there was 
insufficient evidence to recommend any individual type of 
prosthetic ankle-foot mechanism. This trial will establish 
the feasibility of conducting a large-scale trial to assess 
the effectiveness and cost-effectiveness of a self-aligning 
prosthesis for older patients with vascular-related 
amputations and other health issues compared with a 
standard prosthesis.
Methods and analysis This feasibility trial is a pragmatic, 
parallel group, randomised controlled trial (RCT) comparing 
standard treatment with a more rigid prosthesis versus 
a self-aligning prosthesis. The target sample size is 90 
patients, who are aged 50 years and over, and have a 
transtibial amputation, where amputation aetiology is 
mostly vascular-related or non-traumatic. Feasibility will 
be measured by consent and retention rates, a plausible 
future sample size over a 24-month recruitment period and 
completeness of outcome measures. Qualitative interviews 
will be carried out with trial participants to explore issues 
around study processes and acceptability of the intervention. 
Focus groups with staff at prosthetics centres will explore 
barriers to successful delivery of the trial. Findings from the 
qualitative work will be integrated with the feasibility trial 
outcomes in order to inform the design of a full-scale RCT.
Ethics and dissemination Ethical approval was granted 
by Yorkshire and the Humber—Leeds West Research 
Ethics Committee on 4 May 2018. The findings will be 
disseminated via peer-reviewed research publications, 
articles in relevant newsletters, presentations at relevant 
conferences and the patient advisory group.
trial registration number ISRCTN15043643.
IntroduCtIon
The number of people with a lower limb 
amputation is growing and is predicted to 
double in developed nations by the year 
2050.1 In the UK, there are approximately 
6000 new referrals to prosthetics services every 
year, most commonly at the transtibial level.2 3 
Most lower limb amputations (60%–80%) are 
related to ischaemia, vascular atheroscle-
rotic disease and diabetic complications, 
and typically occur in people over 50 years 
of age.3 4 A retrospective review of hospital 
data in England reported that there were 
25 312 lower limb amputations for patients 
aged between 50 and 84 years between 1 April 
2003 and 31 March 2009.5 Therefore, most 
new referrals for a prosthesis involve older 
patients who usually present with multiple 
health comorbidities.
Prosthetic prescription, one important 
factor in the long-term outcomes following 
amputation, is multifaceted, and influenced 
by factors such as estimation of patient 
outcomes, patient goals and budget.6 Prac-
tice varies across UK prosthetics centres and 
is frequently cost-driven. In December 2016, 
NHS England issued its Clinical Commis-
sioning Policy guidelines for the routine 
strengths and limitations of this study
 ► This will be one of the few studies involving older 
amputees in research.
 ► Should it be determined that a larger scale ran-
domised controlled trail is feasible, the information 
collected in this study will be vital in influencing the 
design.
 ► The proposed sample size is large enough to allow 
for reliable estimates to be obtained for calculating 
a future sample size for a main trial.
 ► The study is not large enough to determine effective-
ness and is limited to assess the feasibility aspect.
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prescription of microprocessor-controlled prosthetic 
knees for people with a transfemoral amputation.7 The 
recent clinical commissioning policy is ground-breaking 
for people with a transfemoral amputation, but presents 
no advantage for the prescription of a prosthesis for 
individuals with an amputation at the transtibial level. A 
Cochrane Review concluded that there was insufficient 
evidence from ‘high-quality comparative studies for the 
overall superiority of any individual type of prosthetic 
ankle-foot mechanism’ in patients with a lower limb ampu-
tation.8 Subsequently, the majority of older people with 
a transtibial amputation, often due to vascular reasons, 
are prescribed a standard prosthesis, such as the non-ar-
ticulated solid ankle cushioned heel (SACH), uniaxial or 
multiaxial prosthetic foot. These prostheses are unable to 
adjust to the different walking surfaces people encounter 
daily (ie, uneven terrain, slopes and stairs). This makes 
walking more difficult, less energy efficient and more 
tiring, and may lead to longer term disuse.
Lower limb amputation, and its associated health comor-
bidities (ie, disease status, age-related and amputation-re-
lated complications, pain and sedentary behaviour), 
present a burden for patients (and their carers). Patients 
often report having problems related to mobility, which 
subsequently impacts negatively on their independence, 
and socioeconomic well-being,9 10 especially among older, 
vascular amputees.11 Identifying a suitably functional 
prosthesis could bring many benefits to a patient’s life 
following amputation.
People with a lower limb amputation are an under-rep-
resented group of patients, with little research being 
carried out involving those aged over 50 years. We carried 
out a number of public involvement sessions in order 
to refine our study aims and identify elements of partic-
ular resonance with older individuals following their 
amputation. Public involvement members, who experi-
enced reduced mobility, identified their standard pros-
thesis as a limiting factor in their everyday function. A 
poorly functioning prosthesis often contributed to seden-
tary behaviour, pain, more frequent visits to healthcare 
services, disuse of the prosthesis and possible isolation 
and overall poor quality-of-life.
In order to clearly identify an amputee’s current and 
potential functional status the insurance group, Medi-
care, established Medicare Functional Classification 
Levels (also called K levels) in 1995, which is widely used 
internationally. It is a method of quantifying need and 
the potential benefit of prosthetic devices for those with 
a lower limb amputation. Five classification levels (K0: 
low functional level to K4: high functional level) were 
established.12 An alternative classification system is the 
SIGAM (Special Interest Group in Amputee Medicine) 
developed by the British Society of Rehabilitation Medi-
cine which measures levels of mobility (grade A: lowest 
mobility to grade F: highest mobility).13 A self-aligning 
prosthesis has been designed specifically for the K2 user, 
categorised as ‘limited mobility’, to alleviate many of the 
patient-reported limitations of a standard prosthesis. 
This prosthesis adjusts to slopes and steps via hydraulic 
mechanisms. A self-aligning prosthesis can improve 
ground clearance to avoid a fall, and aligns to secure the 
biological knee in individuals with a transtibial amputa-
tion, which is important for falls prevention.14 Based on 
laboratory studies, this type of self-aligning prosthesis also 
has demonstrated reduced residuum-socket interface 
pressures,15 which could alleviate pain in the residuum 
longer term. Although a self-aligning prosthesis is more 
expensive than a standard prosthesis (by approximately 
£800), the potential patient benefits through increased 
mobility, quality-of-life and fewer falls could offset future 
healthcare and socioeconomic costs. Previous studies 
have shown that more functional prostheses may offer 
better patient function and improve mobility in people 
with a lower limb amputation.16 17 However, these studies 
have not been undertaken in older patients and therefore 
have not considered the health comorbidities that affect 
older, often vascular, patients compared with younger, 
more active amputees.
MEthods And AnAlysIs
Aim and objectives
The primary aim of this study is to determine the feasi-
bility of conducting a full-scale randomised controlled 
trial (RCT) of the effectiveness and cost-effectiveness of a 
self-aligning prosthesis for older patients with vascular-re-
lated amputations and other health issues compared with 
a standard prosthesis.
The specific objectives are to:
 ► Determine patient recruitment rates.
 ► Explore any barriers to recruitment and how these 
might be overcome from the perspective of patients.
 ► Identify the most important outcomes to the patients.
 ► Assess the acceptability of the study procedures to 
both participants and recruiting centres.
 ► Measure patient use of NHS resources over the study 
period.
 ► Identify a primary outcome measure(s) for a future 
main trial.
 ► Assess the completeness of follow-up data, to establish 
how feasible it is to collect patient-reported outcome 
measures.
 ► Measure day-to-day use of the prosthesis in both 
groups and measure normal physical activity through 
the use of wearable technologies (activity monitors).
In addition, the feasibility of a future trial will be 
assessed based on whether:
 ► Study consent/retention rates and proposed sample 
sizes indicate recruitment for the full-scale RCT is 
plausible within a 24-month period.
 ► Outcome measures and fidelity evaluation data are 
successfully collected.
 ► There are no significant barriers to delivery of the 
trial, identified by participants or recruiting centres, 
that cannot be overcome.
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design
The STEPFORWARD trial is a multicentre, mixed-
methods, randomised controlled, open feasibility trial to 
assess the possibility of conducting a full-scale RCT of a 
self-aligning prosthesis for older patients with vascular-re-
lated amputations and other health issues compared with 
a standard prosthesis. The 2-year study commenced on 1 
April 2018; participant recruitment started in July 2018.
settings and participants
Participants who meet the eligibility criteria are being 
recruited from multiple centres based in NHS Trusts 
across England.
Inclusion criteria
A patient is deemed eligible if they meet all the following 
criteria:
1. Aged 50 years or over.
2. Has a unilateral amputation.
3. Has a transtibial amputation only.
4. Has an amputation due to vascular reasons (eg, di-
abetes, peripheral vascular disease), neurological 
disorders (eg, diabetic neuropathy) or life-limiting 
illness (eg, tumour, cancer).
5. Is categorised as ‘limited mobility’: K2 classification, 
or SIGAM mobility grade C or D.
6. Is currently using a standard prosthetic ankle-foot 
(eg, SACH, uniaxial, multiaxial (eg, multiflex) or 
other K1/K2 feet) that does not adjust to sloped sur-
faces and is not self-aligning.
7. Has been using a prosthesis for at least 12 months, 
with the same socket for a minimum of 3 months.
8. Has had a stable residual limb for at least 3 months 
(ie, stable in volume and without cuts or wounds; 
daily management of volume with socks and liners is 
acceptable).
9. Is willing to trial a new prosthesis for a 12-week period 
(if allocated to intervention arm).
10. Is able to self-complete the English language out-
come measure tools (or complete with assistance).
11. Is able to follow the detailed verbal instructions re-
quired for the functional/clinical tests.
12. Is able to provide written informed consent.
Exclusion criteria
Patients will be considered ineligible if any of the 
following apply:
1. Has contraindications of wearing their current pros-
thesis (eg, open wound, infection).
2. Has contraindications of wearing the novel prosthesis 
according to manufacturer’s instructions (eg, body 
mass ≥150 kg; build height (ie, distance between distal 
end of socket and ground) <115 mm).
3. Has had a recent cerebrovascular event, such as a 
stroke.
4. Has a disease that severely affects their memory, such 
as dementia or Alzheimer’s.
sample size
This research is a feasibility RCT and therefore does 
not have a primary outcome measure to inform a power 
calculation. Sample sizes of between 24 and 70 have been 
recommended for feasibility trials to allow for the reliable 
estimation of a SD for use in future sample size calcula-
tions.18 19 We plan to recruit a total of 90 patients in this 
study over a 16-month timeframe. Allowing for a 20% 
attrition rate we intend to have 72 patients in the final 
analysis.
randomisation
Following the completion of all baseline measures, partic-
ipants will be randomised into one of two trial arms: 
standard prosthesis (standard treatment) or self-aligning 
prosthesis (novel treatment). Randomisation will be 
performed by the York Trials Unit. Participants will be 
individually randomised and stratified according to pros-
thetics centre on a 1:1 basis.
blinding
By the nature of the interventions used within this study, 
blinding of the participants and investigators is not 
possible and procedures for breaking codes/unblinding 
are not necessary.
Intervention and standard treatment
Novel treatment
The self-aligning ankle-foot prosthesis is called the 
Avalon-K2, manufactured by Blatchford and Sons, UK 
(Patent reg: 5336386). The prosthesis is already commer-
cially available and may be prescribed under the NHS.
Following randomisation, participants in the novel 
treatment group will have an initial meeting with their 
regular prosthetist for fitting of the novel prosthesis. 
Once fitted with the self-aligning prosthesis, participants 
will be asked to acclimatise and ambulate with it as they 
would normally with any new prosthesis for approximately 
12 weeks after fitting (intervention period). They will be 
offered physiotherapy sessions, to ensure their ability to 
ambulate safely with the new prosthesis, based on clinical 
need.
Participants in the novel treatment group will be given 
the option to keep using the novel prosthesis after the 
trial has completed or return to their original prosthesis.
Standard treatment
Participants in the standard treatment group will continue 
using their normal ankle-foot prosthesis. Participants in 
this group will continue to receive standard treatment 
and have access to all clinical services as normal. Standard 
treatment usually consists of routine visits to the consul-
tant and/or patient-initiated visits (ie, normal prosthetics 
maintenance, and/or trouble-shooting due to prosthesis 
malfunction). This group will be asked to go about their 
normal daily routine wearing their standard prosthesis 
for 15 weeks (intervention period plus additional 3 weeks 
to allow for ordering and fitting of new prosthesis for 
participants in the novel group).
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Figure 1 The STEPFORWARD study flowchart.
Participants in the standard treatment group will not be 
offered to sample the self-aligning prosthesis at the end of 
the trial as it is not known whether the novel prosthesis is 
better and more acceptable to patients than the standard 
prosthesis.
Participant identification and recruitment process
All patients with a unilateral, transtibial amputation due 
to non-traumatic reasons will be screened for eligibility. 
The practicalities of using the eligibility criteria will be 
assessed to inform the criteria that may be subsequently 
used in a main trial. Prospective participants will be iden-
tified via two main methods: during a routine clinical visit 
or via screening of the patient database (figure 1).
In clinic
Potentially eligible patients attending for their 
routine appointment to the prosthetics centre will be 
approached and given a study invitation pack. Patients 
may complete a Consent to Contact form during their 
routine appointment, and be screened by a member of 
their multidisciplinary team (MDT) as soon as possible 
thereafter. Alternatively, patients may take the pack 
away to read through, and return their Consent to 
Contact form in the post. Then, the enrolment process 
will follow the one outlined for those identified via data-
base screening.
Database screening
A member of the patient’s routine MDT and/or pros-
thetics centre manager will screen the prosthetics centre’s 
database for suitable patients according to the inclusion 
criteria. Potential participants will be posted a study 
invitation pack. They will be asked to read through the 
documents and return the Consent to Contact form if 
they wish to be contacted about the trial. If no Consent to 
Contact form is received, patients will be contacted by the 
prosthetics centre approximately 2 weeks after expected 
receipt of the invitation pack.
Alternatively, on receipt of the patient’s Consent to 
Contact form, a member of the MDT will contact the 
patient and complete the first section of the Screening 
Form over the telephone. If potentially eligible, the 
patient will be invited to make an appointment in clinic 
for a face-to-face screening to check eligibility and 
complete the outstanding screening questions. If eligible, 
patients will follow the consent process.
Some patients may not meet all of the inclusion criteria 
at the initial screening and would be eligible for a rescreen 
for two reasons: patient has not yet had a stable residual 
limb for at least 3 months, or they presently have a contra-
indication for wearing their current prosthesis. They will 
be contacted after 3 months to reassess their eligibility 
unless they explicitly request otherwise. Patients will only 
be rescreened for eligibility once.
study visits and follow-up
Data will be collected from participants at four time 
points.
Screening visit
Initial screening may be conducted by telephone, but 
all prospective participants must have a final face-to-face 
screening at their prosthetics centre by a member of 
their normal MDT for eligibility. Informed consent will 
be sought from eligible patients by an MDT member and 
according to Good Clinical Practice guidelines.
Baseline assessment
All consenting participants will be asked to complete a 
baseline questionnaire and undergo four clinical assess-
ments at the prosthetics centre. They will be loaned 
an activity monitor (activPAL4, PAL Technologies Ltd, 
Glasgow, UK), which will be fitted onto their prosthesis 
for 1 week after the baseline assessment. After this, they 
will be requested to remove it and return it via post. 
The activity monitor will quantify the time spent during 
walking activities and the number of daily steps taken, 
using their standard prosthesis.
Interim follow-up
All participants will be posted a questionnaire pack 
mid-way through the intervention period (week 9 
post-randomisation). They will be asked to complete and 
return the questionnaires in a prepaid return envelope.
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Table 1 Trial activity and data collection time points
Screening
Baseline assessment 
(in clinic)
Prosthetic fitting 
(weeks 1–3)
Week 9 follow-up 
assessment (postal)
Week 15 assessment 
(postal)
Week 16 follow-up 
assessment (in clinic)
Eligibility screening 
form
X
Consent   X
Questionnaires   
  Demographics   X
  LCI-5   X X X
  Houghton   X X X
  EQ-5D-5L   X X X
  PROMIS 3a ānd 8a   X X X
  Healthcare resource 
use
  X X X
Clinical assessments   
  2mWT   X X
  TUG   X X
  TUDS   X X
  BBS   X X
1 week activity monitor   X X
Novel prosthesis 
treatment group only
  X
BBS, Berg Balance Scale; LCI-5, Locomotor Capabilities Index-5; PROMIS, Patient-Reported Outcomes Measurement Information System; TUDS, Timed Up and Down 
Stair test; TUG, Timed Up and Go test; 2mWT, 2 min walk test.
Final follow-up
Participants will be posted an activity monitor in the 
week prior to their final follow-up assessment (15 weeks 
post-randomisation), and asked to fit the activity monitor 
onto their prosthesis to monitor their daily stepping 
with the prosthesis they are currently using. The activity 
monitor will be removed when the participant attends the 
prosthetics centre for their final study visit. Participants 
will also be asked to complete the same questionnaire and 
clinical assessments as they did at baseline.
outcome measures
Table 1 details the information to be collected according 
to time points. The participant questionnaires include 
the following.
 ► Locomotor Capabilities Index-5.20
 ► Houghton Scale—prosthetic use in people with lower 
extremity amputations.21
 ► Patient-Reported Outcomes Measurement Informa-
tion System (PROMIS) Short-Form v1.0 Pain (3a and 
8a) questionnaires.22
 ► EQ-5D-5L.23
 ► Bespoke health resource use questionnaire.
The four clinical assessments will be carried out at 
baseline with the participant wearing their standard pros-
thesis and repeated at final follow-up, wearing whichever 
prosthesis they are using at the time. Participants may also 
use their regular walking aid and choose not to attempt 
some assessments. The assessments are as follows.
 ► 2-min walk test.24
 ► Timed-Up and Go test.25
 ► Timed-Up and Down test.26
 ► Berg Balance Scale.27
Qualitative data collection
Semi-structured interviews will be undertaken with 20–25 
participants to explore their experience of being involved 
in the trial, acceptability of the study design, randomisa-
tion and other study processes, and acceptability of the 
intervention. Participants will be purposively selected, we 
aim to sample approximately 8–10 participants from each 
of the novel prosthesis and standard prosthesis arms, 
and approximately five patients who declined to partic-
ipate or dropped out of the trial to explore reasons for 
non-participation. We appreciate that the non-participant 
group may be difficult to reach and will only approach 
individuals who, at the time they declined to partici-
pate, indicated they were happy to be contacted with a 
view to being potentially interviewed. Purposive selection 
will ensure maximum variation across the sample with 
regard to age and gender. The proposed sample of inter-
viewees is likely to achieve data saturation whereby similar 
themes emerge.28 29 A flexible interview schedule will be 
developed.
Focus groups will also be conducted with staff 
(including clinicians, physiotherapists, prosthetists and 
centre managers) at each participating prosthetics centre 
to discuss any barriers to successful delivery of the trial. 
Findings from the qualitative work will be integrated with 
the feasibility trial outcomes in order to inform the design 
of a full-scale RCT.
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All interviews and focus groups will be audio recorded 
with permission. Recordings will be transcribed verbatim 
by approved transcribers and anonymised. A second 
researcher will check a sample of data transcripts against 
the audio recordings for accuracy, and will interrogate 
the validity of the coding against the raw data. Data will be 
entered into appropriate software for thematic analysis.
statistical analyses
A statistical analysis plan detailing intended analyses will 
be drafted before the completion of data collection. The 
trial will be reported according to the CONSORT guide-
lines for feasibility and pilot trials and the flow of partic-
ipants through the trial will be detailed in a CONSORT 
flow diagram.
Baseline data will be summarised by trial arm, as 
randomised, with no formal comparison between the 
groups. Continuous data will be reported descriptively 
(mean, SD, median, minimum, maximum and number 
missing), and categorical data by counts and percent-
ages. No formal statistical analyses will be undertaken as 
this is a feasibility study. Completion rates of all the clin-
ical outcome measures will be reported by trial arm and 
overall.
The recruitment rate will be reported monthly, and 
overall, by centre. An average monthly recruitment rate 
will be calculated, and a 95% CI will be estimated from 
the data collected. This could be used to inform recruit-
ment rates per site in a future main trial and determine 
if an adequate sample could be recruited in ≥24 months 
in a larger trial. The number of eligible patients will be 
summarised overall, by site, using counts and percent-
ages. Reasons for ineligibility will be detailed in the 
CONSORT diagram. The following will also be reported, 
the proportion of:
 ► Eligible patients approached for consent.
 ► Patients approached who provide consent.
 ► Patients approached who do not provide consent.
 ► Patients providing consent who are randomised.
 ► Patients dropping out between randomisation and 
follow-up.
health economic analysis
A full cost-effectiveness analysis will not be undertaken as 
part of the current study. Rather, the work will identify the 
feasibility of collecting the data, needed for an economic 
analysis of a full-scale trial. Health service resource use will 
be collected from participants using a bespoke question-
naire that will include items such as hospital attendances 
and admissions and also primary care visits (eg, GP, phys-
iotherapist and prosthetist). The costing approach will be 
undertaken from an NHS perspective and unit costs will 
be derived from established national costing sources such 
as NHS Reference Costs30 and Personal Social Services 
Research Unit costs of health and social care.31 The costs 
of providing the novel prosthesis will be estimated and 
the potential resource implications versus the standard 
prosthesis will be explored.
safety measurements
Adverse events (AEs) related to the prosthesis only, and any 
serious adverse event (SAE), will be recorded throughout 
the study. Intensity and relationship to the study inter-
vention will be described. Ongoing review of AEs and 
SAEs will take place during monthly Trial Management 
Group (TMG) meetings, discussed with the Patient Advi-
sory Group (PAG) and Trial Steering Committee (TSC), 
and reported to the sponsor and ethics committee in line 
with their guidelines. Participants may withdraw from the 
study at any time without influencing their future care or 
treatment.
trial monitoring and oversight
Due to the low risk nature of this trial, there will be one 
independent steering and monitoring committee to 
undertake the roles traditionally undertaken by the TSC 
and Data Monitoring and Ethics Committee. This Trial 
Steering and Monitoring Committee will comprise of 
independent members including a Chair, a statistician, 
one other independent person, and a member of the 
PAG.
The TMG, comprising the chief investigator, the York 
Trials Unit and coinvestigators, will provide overall 
management of the study. York Trials Unit is respon-
sible for project management. We will establish a PAG 
with between four and eight members that will meet a 
minimum of five times over the duration of the project. 
The PAG is a group of independent patients with an 
amputation and their carers, whose role is to support and 
advise the TMG on all aspects of the study and to facilitate 
its progress and management.
Patient and public involvement
Three funded patient and public involvement (PPI) 
events were carried out at the recruiting sites to inform 
the development of this study. The PPI events helped 
to identify the objectives for the feasibility study, specify 
outcomes that are significant to this patient population, 
and share views on the randomisation process. This has 
enabled the team to prioritise outcome measures related 
to amputee patient function and well-being, and explore 
how to introduce the study to potential participants 
while taking into account their valid concerns about 
randomisation.
data collection, integrity and management
Data will be collected through paper questionnaires 
identified by a unique identification number only (ie, 
the participant identification number in all manual and 
electronic files). Each site will hold data according to the 
General Data Protection Regulation (May 2018). A Trial 
Enrolment Log at the sites will list the participant identi-
fication numbers. York Trials Unit will maintain a list of 
participant identification numbers for all trial patients at 
each site.
All paper documents will be stored securely. All 
information collected will be stored on a secure 
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password-protected server located at the University of 
York, for the purpose of assisting in follow-ups during the 
study and will be kept strictly confidential.
The confidentiality of participants and staff interviewed 
during the qualitative interviews will be ensured by assigning 
a unique participant number to electronic sound files and 
transcripts, known only to the qualitative researcher and 
appropriate members of the research team. Any quotes 
published will be anonymous. All data collected will be 
archived for ten years following the end of the study.
Ethics and dissemination
Yorkshire and The Humber—Leeds West Research Ethics 
Committee granted ethical approval for this study on 4 
May 2018. Since the study started, the Health Research 
Authority approved three substantial amendments to the 
protocol which are included in the final version reported 
here.
1. Inclusion of clear written and pictorial instructions 
for fitting the activity monitor to the participant’s 
prosthesis.
2. Alteration to the recruitment process such that staff 
at the local prosthetics centre could contact a poten-
tial participant after invitations packs had been sent to 
them.
3. Inclusion of a cover letter to accompany the partici-
pant information sheet for the qualitative interview 
aspect of the study.
The proposed study will be conducted in accordance 
with the Medical Research Council Guidelines on Good 
Clinical Practice in Clinical Trials.
The results will inform the design and delivery of 
a definitive RCT. The findings from this study will be 
presented to relevant groups such as the British Associa-
tion of Chartered Physiotherapists in Amputee Rehabili-
tation (BACPAR) and the British Association of Orthotists 
and Prosthetists (BAPO). Participants will be informed 
of the outcome of the study. With the help of our PAG 
representatives, the findings will be disseminated to 
participants, other patients and their carers, and rele-
vant patient support groups, including national charities 
supporting individuals following limb loss. The results will 
also be submitted to the funders, peer-reviewed journals, 
presented at relevant meeting/conferences, including 
participating recruitment sites.
ConClusIon
There is limited robust evidence about the benefits of 
prescribing a self-aligning prosthesis for patients over the 
age of 50 years, who are predominantly prescribed a stan-
dard (ie, more rigid) prosthesis. The outcomes from this 
study will inform a larger fully powered RCT designed to 
determine the effectiveness of a self-aligning prosthesis in 
improving a patient’s daily mobility.
Author affiliations
1York Trials Unit, Department of Health Sciences, University of York, York, UK
2School of Science and Technology, Nottingham Trent University, Nottingham, UK
3United National Institute for Prosthetics & Orthotics Development, University of 
Salford, Salford, UK
4Specialist Mobility Rehabilitation Centre, Lancashire Teaching Hospitals NHS 
Foundation Trust, Preston, UK
5Disability Medicine and Rehabilitation Unit, Hull University Teaching Hospitals NHS 
Trust, Hull, UK
6Public involvemment member, Hull, UK
7Department of Sport, Health and Exercise Science, University of Hull, Hull, UK
Acknowledgements The authors would like to thank the members of the Patient 
Advisory Group (PAG): Dennis Harrison, Peter Wignall, Anthony Gick and Kevin Waller 
for their invaluable advice on many aspects of the project.
Contributors NV led on the conception, design and writing of the study. NM led 
on the writing of the study protocol with substantial contributions to the design, 
writing, critical review of intellectual content and final manuscript approval from 
NV, EC, JW, KB, CMcD, CB, MT, FJ, AS and DH. All authors agree to be accountable 
for their work. As Chief Investigator, NV takes overall responsibility for the work. 
EC provided statistical expertise in the study design and development stages of 
the project and the protocol. NM, JW, and CMcD made substantial contributions 
to the trial design and management. DH provided particular input to PPI. KB was 
specifically responsible for the health economic aspects of the study design and 
CB, MT, FJ and AS were responsible for providing expert clinical support.
Funding Hull University Teaching Hospitals NHS Trust are the sponsors on behalf 
of the funder, who is the NIHR as stated below. This paper presents independent 
research funded by the National Institute for Health Research (NIHR) under 
its Research for Patient Benefit (RfPB) Programme (Grant Reference Number 
PB-PG-0816-20029). Blatchford and Sons (UK) have provided the prosthetic feet 
examined in this research at no cost. The prosthetic feet are currently commercially 
available devices. Blatchford and Sons have had no part in the study design, nor 
are they involved directly in the research, its subsequent analysis and ultimate 
dissemination.
disclaimer The views expressed are those of the author(s) and not necessarily 
those of the NHS, the NIHR, the Department of Health and Social Care, or Blatchford 
and Sons.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval Ethical approval by Yorkshire and The Humber – Leeds West 
Research Ethics Committee (IRAS project ID 232950; REC reference 18/YH/0089) 
and HRA approval were obtained on 4 May 2018.
Provenance and peer review Not commissioned; peer reviewed for ethical and 
funding approval prior to submission.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
rEFErEnCEs
 1. Ziegler-Graham K, MacKenzie EJ, Ephraim PL, et al. Estimating the 
prevalence of limb loss in the United States: 2005 to 2050. Arch Phys 
Med Rehabil 2008;89:422–9.
 2. Limbless Statisitcs, annual report 2011-2012. University of Salford, 
UK. UNIPOD – United National Institute for Prosthetics & Orthotics 
Development; 2015.
 3. National Amputee Statistical Database (NASDAB). The amputee 
statistical database for the United Kingdom 2006/07. Information 
Services Division NHS Scotland; 2009.
 4. Dillingham TR, Pezzin LE, MacKenzie EJ. Limb amputation and limb 
deficiency: epidemiology and recent trends in the United States. 
South Med J 2002;95:875–83.
 5. Ahmad N, Thomas GN, Gill P, et al. Lower limb amputation in 
England: prevalence, regional variation and relationship with 
revascularisation, deprivation and risk factors. A retrospective review 
of hospital data. J R Soc Med 2014;107:483–9.
 6. Sansam K, O'Connor RJ, Neumann V, et al. Clinicians' perspectives 
on decision making in lower limb amputee rehabilitation. J Rehabil 
Med 2014;46:447–53.
copyright.
 o
n
 O
ctober 22, 2019 at Uni of Hull Consortia. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-032924 on 20 September 2019. Downloaded from 
8 Mitchell N, et al. BMJ Open 2019;9:e032924. doi:10.1136/bmjopen-2019-032924
Open access 
 7. NHS England Specialised Services Clinical Reference Group for 
Complex Disability Equipment- Prosthetics. Clinical commissioning 
policy: microprocessor controlled prosthetic knees.NHS England 
16061/P; December 2016.
 8. Hofstad CJ, van der Linde H, van Limbeek J, et al. Prescription 
of prosthetic ankle-foot mechanisms after lower limb amputation. 
Cochrane Db Syst Rev 2004;4.
 9. Miller WC, Deathe AB, Speechley M. Lower extremity prosthetic 
mobility: a comparison of 3 self-report scales. Arch Phys Med 
Rehabil 2001;82:1432–40.
 10. Miller WC, Speechley M, Deathe B. The prevalence and risk factors 
of falling and fear of falling among lower extremity amputees. Arch 
Phys Med Rehabil 2001;82:1031–7.
 11. Jordan RW, Marks A, Higman D. The cost of major lower 
limb amputation: a 12-year experience. Prosthet Orthot Int 
2012;36:430–4.
 12. Agrawal V, Gailey RS, Gaunaurd IA, et al. Comparison of four 
different categories of prosthetic feet during ramp ambulation in 
unilateral transtibial amputees. Prosthet Orthot Int 2015;39:380–9.
 13. Ryall NH, Eyres SB, Neumann VC, et al. The SIGAM mobility grades: 
a new population-specific measure for lower limb amputees. Disabil 
Rehabil 2003;25:833–44.
 14. Johnson L, De Asha AR, Munjal R, et al. Toe clearance when walking 
in people with unilateral transtibial amputation: effects of passive 
hydraulic ankle. J Rehabil Res Dev 2014;51:429–38.
 15. Portnoy S, Kristal A, Gefen A, et al. Outdoor dynamic subject-
specific evaluation of internal stresses in the residual limb: hydraulic 
energy-stored prosthetic foot compared to conventional energy-
stored prosthetic feet. Gait Posture 2012;35:121–5.
 16. Goujon H, Bonnet X, Sautreuil P, et al. A functional evaluation of 
prosthetic foot kinematics during lower-limb amputee gait. Prosthet 
Orthot Int 2006;30:213–23.
 17. Barnett CT, Brown OH, Bisele M, et al. Individuals with unilateral 
transtibial amputation and lower activity levels walk more quickly 
when using a Hydraulically Articulating versus rigidly attached 
prosthetic Ankle-Foot device. J Prosthet Orthot 2018;30:1–164.
 18. Julious SA. Sample size of 12 per group rule of thumb for a pilot 
study. Pharm Stat 2005;4:287–91.
 19. Teare MD, Dimairo M, Shephard N, et al. Sample size requirements 
to estimate key design parameters from external pilot randomised 
controlled trials: a simulation study. Trials 2014;15:264.
 20. Franchignoni F, Orlandini D, Ferriero G, et al. Reliability, validity, and 
responsiveness of the locomotor capabilities index in adults with 
lower-limb amputation undergoing prosthetic training. Arch Phys 
Med Rehabil 2004;85:743–8.
 21. Devlin M, Pauley T, Head K, et al. Houghton scale of prosthetic use 
in people with lower-extremity amputations: reliability, validity, and 
responsiveness to change. Arch Phys Med Rehabil 2004;85:1339–44.
 22. Morgan SJ, Friedly JL, Amtmann D, et al. Cross-Sectional 
assessment of factors related to pain intensity and pain 
interference in lower limb prosthesis users. Arch Phys Med Rehabil 
2017;98:105–13.
 23. Hurst NP, Kind P, Ruta D, et al. Measuring health-related quality of 
life in rheumatoid arthritis: validity, responsiveness and reliability of 
EuroQol (EQ-5D). Rheumatology 1997;36:551–9.
 24. Butland RJA, Pang J, Gross ER, et al. 2-Minute, 6-minute, and 
12-minute walking tests in respiratory-disease. BMJ 1982;284:1607.
 25. Podsiadlo D, Richardson S. The Timed “Up & Go”: A Test of Basic 
Functional Mobility for Frail Elderly Persons. J Am Geriatr Soc 
1991;39:142–8.
 26. Bonnyaud C, Zory R, Pradon D, et al. Clinical and biomechanical 
factors which predict timed up and down stairs test performance in 
hemiparetic patients. Gait Posture 2013;38:466–70.
 27. Major MJ, Fatone S, Roth EJ. Validity and reliability of the Berg 
balance scale for community-dwelling persons with lower-limb 
amputation. Arch Phys Med Rehabil 2013;94:2194–202.
 28. Schaffalitzky E, Gallagher P, Maclachlan M, et al. Understanding 
the benefits of prosthetic prescription: exploring the experiences 
of practitioners and lower limb prosthetic users. Disabil Rehabil 
2011;33:1314–23.
 29. Strauss A, Corbin J. Basics of qualitative research: Techniques and 
procedures for developing grounded theory. (2nd ed.). Thousand 
Oaks, CA, US: Sage Publications, Inc., 1998.
 30. Department of Health. NHS reference costs 2017/18. London, 2018. 
Available: https:// improvement. nhs. uk/ resources/ reference- costs/# 
rc1718
 31. Curtis L, Burns A. Unit costs of health and social care 2018, personal 
social services research unit. Canterbury: University of Kent, 2018.
copyright.
 o
n
 O
ctober 22, 2019 at Uni of Hull Consortia. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-032924 on 20 September 2019. Downloaded from 
